Skip to main content

ADMA Biologics Value Stock - Dividend - Research Selection

Adma biologics

ISIN: US0008991046 , WKN: A12FAG

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


ADMA Biologics : Certificate of Incorporation/Bylaws Form 8 K

2024-06-28
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. ...

Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?

2024-06-27
Based on the average brokerage recommendation (ABR), Adma Biologics (ADMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know

2024-06-26
Adma Biologics (ADMA) concluded the recent trading session at $10.84, signifying a -1.54% move from its prior day's close.

Adma Biologics (ADMA) Increases Despite Market Slip: Here's What You Need to Know

2024-06-20
In the most recent trading session, Adma Biologics (ADMA) closed at $10.71, indicating a +0.85% shift from the previous trading day.

Peeling Back The Layers: Exploring ADMA Biologics Through Analyst Insights

2024-06-20
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Adma Biologics price target raised by $2 at Mizuho, here's why

2024-06-20
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Could Be 36% Below Their Intrinsic Value Estimate

2024-06-17
Key Insights The projected fair value for ADMA Biologics is US$16.66 based on 2 Stage Free Cash Flow to Equity ADMA...

Wall Street Breakfast: The Week Ahead

2024-06-16

Catalyst Watch: HP Enterprise event, Walmart+ Week, Pure Storage buzz, and triple-witching volatility

2024-06-14
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Wall Street Analysts Think Adma Biologics (ADMA) Is a Good Investment: Is It?

2024-06-11
Based on the average brokerage recommendation (ABR), Adma Biologics (ADMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?